Connor, Clark & Lunn Investment Management Ltd. Biocryst Pharmaceuticals Inc Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$26 Billion
Q2 2025

A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 1,257,691 shares of BCRX stock, worth $10.8 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

1,257,691

Previous 1,042,424 20.65%

Holding current value

$10.8 Million

Previous $7.82 Million 44.13%

% of portfolio

0.04%

Previous 0.04%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 07, 2025	BUY	$6.41 - $11.19 $1.38 Million - $2.41 Million	215,267 Added 20.65%	1,257,691 $11.3 Million
Q1 2025 May 12, 2025	BUY	$7.06 - $9.39 $2.88 Million - $3.84 Million	408,560 Added 64.46%	1,042,424 $7.82 Million
Q4 2024 Feb 10, 2025	SELL	$7.03 - $8.43 $340,673 - $408,517	-48,460 Reduced 7.1%	633,864 $4.77 Million
Q3 2024 Nov 08, 2024	SELL	$6.41 - $8.69 $643,179 - $871,954	-100,340 Reduced 12.82%	682,324 $5.19 Million
Q2 2024 Aug 09, 2024	BUY	$4.13 - $6.79 $261,106 - $429,277	63,222 Added 8.79%	782,664 $4.84 Million
Q1 2024 May 09, 2024	BUY	$4.89 - $7.65 $135,668 - $212,241	27,744 Added 4.01%	719,442 $3.65 Million
Q4 2023 Feb 09, 2024	BUY	$4.98 - $6.77 $741,631 - $1.01 Million	148,922 Added 27.44%	691,698 $4.14 Million
Q3 2023 Nov 13, 2023	BUY	$6.71 - $7.92 $949,914 - $1.12 Million	141,567 Added 35.29%	542,776 $3.84 Million
Q2 2023 Aug 10, 2023	BUY	$6.96 - $8.81 $373,042 - $472,198	53,598 Added 15.42%	401,209 $2.82 Million
Q1 2023 May 09, 2023	BUY	$7.94 - $11.84 $2.54 Million - $3.79 Million	319,815 Added 1150.58%	347,611 $2.9 Million
Q4 2022 Feb 10, 2023	BUY	$10.5 - $14.2 $291,858 - $394,703	27,796 New	27,796 $319,000
Q2 2022 Aug 05, 2022	SELL	$7.89 - $17.88 $729,272 - $1.65 Million	-92,430 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$11.56 - $19.76 $1.07 Million - $1.83 Million	92,430 New	92,430 $1.5 Million
Q3 2021 Nov 12, 2021	SELL	$14.21 - $17.65 $687,081 - $853,412	-48,352 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$9.5 - $17.24 $459,344 - $833,588	48,352 New	48,352 $764,000
Q2 2020 Aug 13, 2020	SELL	$1.9 - $5.61 $1.16 Million - $3.43 Million	-611,934 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$1.6 - $4.11 $695,123 - $1.79 Million	434,452 Added 244.79%	611,934 $1.22 Million
Q4 2019 Feb 12, 2020	BUY	$1.59 - $3.45 $282,196 - $612,312	177,482 New	177,482 $612,000
Q2 2018 Aug 02, 2018	SELL	$4.6 - $6.52 $74,763 - $105,969	-16,253 Closed	0 $0
Q1 2018 May 14, 2018	SELL	$4.35 - $5.82 $92,546 - $123,820	-21,275 Reduced 56.69%	16,253 $78,000
Q4 2017 Feb 09, 2018	SELL	$4.16 - $5.33 $47,120 - $60,372	-11,327 Reduced 23.18%	37,528 $184,000
Q3 2017 Nov 14, 2017	BUY	$4.1 - $5.97 $200,305 - $291,664	48,855	48,855 $256,000

Others Institutions Holding BCRX

# of Institutions

292

Shares Held

177M

Call Options Held

721K

Put Options Held

489K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.6B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account

Connor, Clark & Lunn Investment Management Ltd. Biocryst Pharmaceuticals Inc Transaction History